Business
Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
(TheNewswire) LONDON, ONTARIO - TheNewswire – December 16, 202...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n LONDON, ONTARIO -\n \n \n TheNewswire\n \n \n – December 16, 2021 –\nSernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage\nregenerative medicine and cell therapy therapeutics company focused on\ndeveloping a potential ‘functional cure’ for type 1 diabetes (T1D)\nand other chronic diseases, is pleased to announce\n \n \n \n \n that Dr. Piotr Witkowski, principal\ninvestigator of Sernova’s Phase I/II clinical trial will present\nupdated interim results from the ongoing safety, tolerability and\nefficacy study of Sernova’s Cell Pouch™ in a poster session at the\nAmerican Society of Transplant Surgeons (ASTS) 22nd Annual “State of\nthe Art” Winter Symposium on January 13, 2022.\n \n \n \n \n Dr. Witkowski’s presentation entitled,\n \n \n A Modified Approach for Improved Islet\nAllotransplantation into the Pre-vascularized Sernova Cell Pouch™\ndevice-preliminary results of the phase I and II clinical study at\nUniversity of Chicago,\n \n \n will be presented\n \n \n to more than 600 transplant professionals as part of\nAbstract Session A, starting at 5:30 PM. Further details on the\nprogram and registration can be found on the ASTS Winter Symposium\nwebsite:\n \n \n \n \n https://asts.org/events-meetings/winter-symposium\n \n \n \n \n \n \n The ASTS Winter Symposium is the same conference where,\nin January 2021, Dr. Witkowski presented positive preliminary safety\nand efficacy data indicating that Sernova’s Cell Pouch™\ntransplanted with insulin producing cells in patients with type 1\ndiabetes showed persistent islet function and clinically meaningful\nimprovement in measures of glucose control.\n \n \n \n \n \n \n \n ABOUT ASTS AND THE 22nd ANNUAL\nSTATE OF THE ART WINTER SYMPOSIUM\n \n \n \n \n The American Society of Transplant Surgeons represents\napproximately 1,900 professionals, regulatory authorities and\npharmaceutical representatives dedicated to excellence in\ntransplantation surgery. ASTS advances the art and science of\ntransplant surgery through patient care, research, education, and\nadvocacy.\n \n \n \n \n ABOUT SERNOVA\n \n \n \n \n Sernova ...